271 related articles for article (PubMed ID: 19320528)
1. Cytochrome P450 2D6 genotyping: potential role in improving treatment outcomes in psychiatric disorders.
Kirchheiner J; Rodriguez-Antona C
CNS Drugs; 2009; 23(3):181-91. PubMed ID: 19320528
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
Zhou SF
Clin Pharmacokinet; 2009; 48(12):761-804. PubMed ID: 19902987
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics in psychiatry--a useful clinical tool or wishful thinking for the future?
Kirchheiner J; Seeringer A; Viviani R
Curr Pharm Des; 2010; 16(2):136-44. PubMed ID: 20205659
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
Kirchheiner J; Seeringer A
Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
[TBL] [Abstract][Full Text] [Related]
5. Recognition of impaired atomoxetine metabolism because of low CYP2D6 activity.
ter Laak MA; Temmink AH; Koeken A; van 't Veer NE; van Hattum PR; Cobbaert CM
Pediatr Neurol; 2010 Sep; 43(3):159-62. PubMed ID: 20691935
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics and drug therapy in psychiatry--the role of the CYP2D6 polymorphism.
Vandel P; Talon JM; Haffen E; Sechter D
Curr Pharm Des; 2007; 13(2):241-50. PubMed ID: 17269931
[TBL] [Abstract][Full Text] [Related]
8. Have we successfully implemented CYP2D6 genotyping in psychiatry?
de Leon J
Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1201-1203. PubMed ID: 29164956
[No Abstract] [Full Text] [Related]
9. CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
Rodríguez-Antona C; Gurwitz D; de Leon J; Llerena A; Kirchheiner J; de Mesa EG; Ibarreta D
Pharmacogenomics; 2009 Apr; 10(4):685-99. PubMed ID: 19374522
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of psychotropic drug response.
Malhotra AK; Murphy GM; Kennedy JL
Am J Psychiatry; 2004 May; 161(5):780-96. PubMed ID: 15121641
[TBL] [Abstract][Full Text] [Related]
11. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
Brown JT; Bishop JR
Pharmacogenomics; 2015; 16(13):1513-20. PubMed ID: 26314574
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs.
Dorado P; Berecz R; Peñas-Lledó EM; Cáceres MC; Llerena A
Curr Drug Targets; 2006 Dec; 7(12):1671-80. PubMed ID: 17168842
[TBL] [Abstract][Full Text] [Related]
13. Personalized medicine in psychiatry: new technologies and approaches.
Costa e Silva JA
Metabolism; 2013 Jan; 62 Suppl 1():S40-4. PubMed ID: 23018148
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
Yu G; Li GF; Markowitz JS
J Child Adolesc Psychopharmacol; 2016 May; 26(4):314-26. PubMed ID: 26859445
[TBL] [Abstract][Full Text] [Related]
15. Clinical applications of CYP genotyping in psychiatry.
Spina E; de Leon J
J Neural Transm (Vienna); 2015 Jan; 122(1):5-28. PubMed ID: 25200585
[TBL] [Abstract][Full Text] [Related]
16. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
Michelson D; Read HA; Ruff DD; Witcher J; Zhang S; McCracken J
J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):242-51. PubMed ID: 17242628
[TBL] [Abstract][Full Text] [Related]
17. Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.
Notsu Y; Shimizu M; Sasaki T; Nakano A; Ota M; Yoshida S; Yamazaki H
Drug Metab Pharmacokinet; 2020 Apr; 35(2):191-200. PubMed ID: 32184039
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics for the individualization of psychiatric treatment.
Arranz MJ; Collier D; Kerwin RW
Am J Pharmacogenomics; 2001; 1(1):3-10. PubMed ID: 12173312
[TBL] [Abstract][Full Text] [Related]
19. Is pharmacogenetic CYP2D6 testing useful?
Vetti HH; Molven A; Eliassen AK; Steen VM
Tidsskr Nor Laegeforen; 2010 Nov; 130(22):2224-8. PubMed ID: 21109842
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report.
Smith T; Sharp S; Manzardo AM; Butler MG
Int J Mol Sci; 2015 Feb; 16(3):4416-28. PubMed ID: 25710722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
